iBET is one of the partners in this EU funded project which aims to develop Innovative Eco-Technologies for Resource Recovery from Wastewater
This is a key instrument in the continued partnership between the Structural Biology for Drug Discovery Unit at iBET in Oeiras and the Molecular Interactions and Biophysics Group at Merck in Darmstadt.
iBET on the National TV news: An innovative clinical trial and the first in Europe with stem cell infusion for cardiac regeneration12.06.2017
1st year results prove to be very promising: no adverse effects or rejection of the cells were observed in the 55 patients tested!
The nomination was announced during its 25th Meeting, held last May in Lausanne, Switzerland.
The 2017 ESACT (European Society of Animal Cell Technology) Meeting took place in Lausanne (May 14-17) and focused on the theme "Cell technologies for innovative therapies".
iBET was present at the XVI Portuguese Congress of Nutrition and Food (4-5 May) at the invitation of its shareholder Buggypower08.05.2017
The meeting joined together over 1500 nutritionists, researchers, MDs and other professionals from the agrofood industry to debate topics aligned with inovation, new food sources, metabolic disorders and healthy aging.
Buggypower is a biotechnology company specialized in the design, construction and operation of microalgae production units.
Rosário Bronze, Associate Professor at the School of Pharmacy of the University of Lisbon (FFUL), is head of the Food Functionality and Bioactives Lab at iBET and ITQB NOVA and of the Toxicological and Bromatology Lab at FFUL.
The EC has officially approved the “TRANSVAC2” project. This project has as coordinating institution the European Vaccine Initiative (EWIV) and a maximum grant amount of 10 M€ for 60 months.
Genibet is a CDMO (Contract Development and Manufacturing Organization) created in 2006, with headquarters in Oeiras and that is dedicated to the manufacture of biopharmaceutical products.